Indoco Remedies Reports Q3 FY25 Loss

  Published 1 year ago

Indoco Remedies, a pharmaceutical company manufacturing allopurinol (generic for Zyloprim) and APIs, reported a net loss of Rs 10.23 crore in Q3 FY25, a significant drop from the profit in Q3 FY24. Revenue also decreased by 18.61%.

  • Allopurinol treats high uric acid levels.
  • Indoco produces both APIs & formulations.
  • Q3 FY25 revenue was Rs 364.91 crore.

You might like these

India's Services Trade May 2025: Exports Rise, Imports Fall

Medplus Shares Slide 4.8% on Q1 Miss

India’s Electronics Export Boom

Sun Pharma Launches Leqselvi in US

Paytm Shares Drop 10% Amid UPI Fee Denial

Avenue Supermarts Surge After CLSA

Cartrade Shares Surge 4.2% on Traffic Spike

News that matters the most ⚡